A new ACC Expert Consensus Decision Pathway aims to fill the gap in clinical care for the management of high-risk atherosclerotic cardiovascular disease (ASCVD) patients with persistent hypertriglyceridemia and the incorporation of triglyceride nonstatin therapies.
↧